Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Financial Performance - On February 5, 2026, Coty reported non-GAAP earnings per share of $0.14, which missed the consensus estimate by $0.04 [3]. - Coty withdrew its full-year 2026 guidance and introduced a turnaround strategy focused on core brands [3]. - Following the announcement, Coty's stock price dropped by $0.49 per share, or 15.56%, closing at $2.66 per share on February 6, 2026 [3].

Core Viewpoint - Bright Horizons Family Solutions Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance and an increase in expected center closures [1][3]. Financial Performance - For the fourth quarter of 2025, Bright Horizons reported a net income of $22 million, which represents a decrease of 25% year-over-year [3]. - The diluted earnings per common share were $0.38, down 24% compared to the previous year [3]. - The company incurred $14.8 million in impairment and lease termination costs due to facility closures [3]. Operational Changes - Bright Horizons announced an expected closure of "45 to 50 or so centers" in 2026, nearly doubling its prior estimate of "25 to 30 or so centers" [3]. - This announcement contributed to a significant drop in the company's stock price, which fell by $14.93 per share, or 18.25%, closing at $66.90 on February 13, 2026 [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving T1 Energy Inc. and its officers or directors [1] Group 1: Company Overview - T1 Energy Inc. is identified as a company listed on the NYSE under the ticker TE [1] - The company has been described as a "Failed EV Battery SPAC" in a short report published by Culper Research [3] Group 2: Stock Performance - Following the publication of the short report, T1's stock price decreased by $0.46 per share, representing a decline of 5.56%, closing at $7.82 per share on January 21, 2026 [3] Group 3: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has a track record of recovering multimillion-dollar damages for class members [4]

Core Viewpoint - The Fermi Inc. class action lawsuit alleges that the company and its executives made misleading statements regarding its Project Matador, leading to significant financial losses for investors following the termination of a key funding agreement [3][4][5]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Lupia v. Fermi Inc., No. 26-cv-00050 (S.D.N.Y.), and it involves purchasers of Fermi's common stock during its IPO and the subsequent Class Period from October 1, 2025, to December 11, 2025 [1]. - Investors have until March 6, 2026, to seek appointment as lead plaintiff in the lawsuit [1][6]. - The lawsuit claims violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 by Fermi and its executives [1]. Group 2: Allegations Against Fermi - The lawsuit alleges that Fermi overstated tenant demand for its Project Matador campus and failed to disclose reliance on a single tenant's funding commitment [3]. - It is claimed that there was a significant risk of the tenant terminating its funding commitment, which was not disclosed to investors [3]. - On December 12, 2025, Fermi announced that the first tenant for Project Matador had terminated a $150 million funding agreement, causing the stock price to drop nearly 34% [4]. Group 3: Financial Impact - Following the termination of the funding agreement, Fermi's stock price fell to as low as $8.59 per share, representing a 59% decline from the IPO price of $21.00 per share [5]. - Fermi sold 37,375,000 shares at the IPO price of $21.00 per share in October 2025 [2]. Group 4: Legal Representation - Robbins Geller Rudman & Dowd LLP is leading the class action lawsuit and is recognized as a top firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a history of significant recoveries in securities class actions, including the largest recovery in history of $7.2 billion in the Enron case [7].

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gartner, Inc. (“Gartner” or the “Company”) (NYSE: IT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Gartner and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On February 3, 2026, G ...

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AMC Entertainment Holdings, Inc. (“AMC” or the “Company”) (NYSE: AMC; APE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether AMC and certai ...

Core Viewpoint - A class action lawsuit has been filed against Franklin BSP Realty Trust, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP if they purchased Franklin securities during the Class Period, with a deadline of April 27, 2026, to apply as Lead Plaintiff [2]. - The lawsuit questions the actions of Franklin and certain officers/directors regarding potential securities fraud [2]. Group 2: Company Performance and Stock Reaction - Franklin appointed a new Chief Executive Officer and President on February 10, 2026, which led to a stock price decline of $0.10 per share, or 0.98%, closing at $10.25 on February 11, 2026 [4]. - The company reported fourth quarter earnings per share of $0.12, missing consensus estimates by $0.16, and revenue of $81.12 million, below the consensus estimate of $93.65 million, resulting in a stock price drop of $1.44 per share, or 14.19%, closing at $8.71 on February 12, 2026 [5]. - The CEO stated that 2025 was a year of transition, indicating delays in resolving and selling certain real estate assets [5].

Core Viewpoint - A class action lawsuit has been filed against Ostin Technology Group Co., Ltd. for alleged securities fraud and unlawful business practices, with significant investor losses reported [2][4]. Group 1: Lawsuit Details - The lawsuit concerns allegations that Ostin and certain officers/directors engaged in a multifaceted securities fraud scheme, resulting in investor losses exceeding $950 million in market capitalization [2][4]. - Investors have until April 17, 2026, to request appointment as Lead Plaintiff if they purchased Ostin securities during the Class Period [2]. Group 2: Financial Impact - The fraudulent promotional campaign inflated Ostin's market capitalization from approximately $22 million (stock price of $0.78 on April 14, 2025) to over $1 billion (peak stock price of $9.40 on June 26, 2025) [4]. - On June 26, 2025, Ostin investors faced significant losses, with over $950 million (more than 94%) of market capitalization lost in a single day as the stock price fell from an intraday high of $9.40 to a closing price of $0.55 [5].

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Regenxbio and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 14, 2026, to request to be appointed as Lead Plaintiff if they purchased Regenxbio securities during the Class Period [2]. Group 2: Recent Developments - On January 28, 2026, Regenxbio announced that the U.S. FDA placed a clinical hold on its investigational gene therapy RGX-111 for MPS I due to a case of neoplasm in a participant [4]. - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [4]. - Following this announcement, Regenxbio's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share on January 28, 2026 [4].

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 21, 2026 [2]. - The lawsuit follows a significant stock price drop after the FDA issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, which was intended for treating hypertension secondary to hypercortisolism [4]. Group 2: Stock Performance - Following the FDA's announcement, Corcept's stock price fell by $35.40 per share, representing a 50.4% decrease, closing at $34.80 per share on December 31, 2025 [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].